AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
3
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
More news

Teva

9 stories about Teva
תרופות טבע גלולות תרופה

Bidders Line Up for Teva’s Women Health Unit, Report Says

23.08.17|Dror Reich
Church & Dwight Co. and Cooper Companies Inc. join other bidders for troubled drugmaker assets, Bloomberg reported Tuesday
Cummings Welch

U.S. Congress to Investigate Rising Multiple Sclerosis Drug Prices

21.08.17|Dror Reich
Two Congressmen are looking into the rising MS drug prices of seven pharmaceutical companies
מפעל טבע הר חוצבים ירושלים

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17|Calcalist
The private equity firms are taking an interest in Teva's European oncology and pain treatment assets, estimated at $700 million to 1$ billion, according to a Bloomberg report
default image

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
מפעל חברת טבע הר חוצבים ירושלים

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist
Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts
מנכ"ל AstraZeneca פסקל סוריו Pascal Soriot

Soriot's Teva Appointment Unlikely, Says Activist Investor

06.08.17|Golan Hazani
Teva’s board was surprised to learn AstraZeneca's CEO Pascal Soriot will not be joining the company. Teva activist investor Benny Landa called an early report on Teva's negotiations with Mr. Soriot "devastating"
default image

Allergan Can Now Sell 9.8% Teva Stake

03.08.17|Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended
מנכ"ל AstraZeneca פסקל סוריו Pascal Soriot

Teva in Talks to Appoint AstraZenca's Pascal Soriot as CEO

18.07.17|Golan Hazani
Mr. Soriot has met with the company’s search committee and its chairman and expressed his agreement to serve as its next CEO, people familiar with the matter said
Previous Articles